Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZP4207 in healthy volunteers and type 1 diabetes
NCT02367053Phase 1Completed
- Sponsor
- Zealand Pharma
- Start
- Dec 2014
- Primary completion
- Apr 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dasiglucagon in hypoglycemia, sponsored by Zealand Pharma. Primary endpoint: Number of participants with adverse events at 28 days. Started Dec 2014; status: completed.
02
Drugs
dasiglucagon
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT02367053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367053.